{"entity":{"id":"shanghai-abelzeta","kind":"company","name":"Shanghai AbelZeta","aka":["Shanghai AbelZeta Ltd."],"tldr":"Shanghai AbelZeta is a China-based cell therapy company running 2 late-stage cancer trials in hepatocellular carcinoma and multiple myeloma.","summary":"Shanghai AbelZeta, based in Shanghai, China, is a cell therapy company. AbelZeta Pharma is a global cell therapy company focused on discovering, developing and manufacturing CAR-T therapeutics for haematologic malignancies, inflammatory and immunological diseases, and solid tumours. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials in hepatocellular carcinoma and multiple myeloma. The largest, NCT06590246 (A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/Recurrent Hepatocellular Carcinoma (HCC)), plans to enrol 121 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.abelzeta.com/"},{"label":"ClinicalTrials.gov: trials led by Shanghai AbelZeta","url":"https://clinicaltrials.gov/search?lead=Shanghai%20AbelZeta%20Ltd."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["hcc","multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06590246","nct05521802"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Shanghai","country":"CN","companyType":"cell-therapy","website":"https://www.abelzeta.com/","investors":[],"funding":[]},"route":"/companies/shanghai-abelzeta/","neighbours":{"cancer":[{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"},{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"trial":[{"id":"nct05521802","kind":"trial","name":"A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct05521802/"},{"id":"nct06590246","kind":"trial","name":"A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/Recurrent Hepatocellular Carcinoma (HCC)","route":"/trials/nct06590246/"}]}}